Regeneron inks drug pricing deal with Trump, will offer hearing-loss therapy for free
U.S. President Donald Trump (C) speaks during an event on improving health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC.
Alex Wong | Getty Images
Regeneration The United States has agreed to lower US drug prices for some Americans as part of a deal with President Donald Trump, the White House said on Thursday.
The biotech company will also offer its first hearing loss gene therapy for free to eligible U.S. patients after the product was approved early Thursday.
Regeneron became the latest in a series of major drugmakers to offer price concessions for new and existing drugs under deals with Trump. These agreements are part of a “most favored nation” effort to tie U.S. drug prices to the lowest prices in other developed countries.
The deals also exempt companies from tariffs for three years, including the up to 100% tariffs Trump plans for some pharmaceutical products. At a White House event on Thursday, CMS deputy administrator Chris Klomp said the Trump administration has signed 17 agreements so far but is negotiating more with other biotech and pharmaceutical companies.
Regeneron’s deal comes just hours after the Food and Drug Administration approved The company’s gene therapy, Otarmeni, restored hearing in a small number of deaf children. The treatment received accelerated approval under the FDA’s National Priority Voucher program.
The drug targets an extremely rare genetic condition caused by a mutation that prevents the body from producing the protein needed for hearing. This is an important breakthrough for a group of patients who have long been dependent on cochlear implants.
Piper Sandler analysts predicted in a March note that the gene therapy would reach peak sales of $130 million.
— CNBC’s Angelica Peebles contributed to this report.
